Boceprevir (Victrelis®)
Economic evaluation of Boceprevir (Victrelis®) as add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1.
Pharmacoeconomic Evaluation
| Commenced | Completed | Outcome |
| 19/08/2011 | 17/01/2012 | Reimbursement Recommended |
We consider boceprevir a highly cost-effective therapy when added to peginterferon-ribavirin for the treatment of patients infected with genotype 1 hepatitis C virus in the Irish healthcare setting
Boceprevir (Victrelis®) summary